On April 12, 2021 Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity, reported translational data for the Company’s lead clinical candidate from a Phase 1 study in patients with advanced solid tumors (Press release, Amphivena Therapeutics, APR 12, 2021, View Source [SID1234577931]). The poster, entitled "MDSC Suppress the T Cell Repertoire and Contribute to a Pathologic Cytokine Milieu in Cancer Patients," (Abstract 528) is presented today at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2021 Virtual Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The translational data we are presenting today at AACR (Free AACR Whitepaper) continue to highlight the unique properties of AMV564 and our broader platform technology. AMV564 relieves immune suppression via MDSC depletion which results in the expansion of anti-tumor T-cells, while attenuating the biological responses that contribute to cytokine release syndrome. These findings are consistent with both the clinical activity and safety profile that we have observed in our phase 1 dose escalation in solid tumor patients, with no CRS at doses of 5 – 50 mcg. As our work advances, we are confident that these data signal an opportunity for AMV564 as a new, safe treatment paradigm for solid tumors," said Victoria Smith, Ph.D., Chief Scientific Officer of Amphivena Therapeutics.
The poster’s authors conclude:
AMV564 selectively depletes M- and G-MDSC with concomitant activation of T cells, thereby relieving systemic immune suppression and preventing pathologic levels of myeloid cytokines
Control of MDSC by AMV564 yields a pro-inflammatory cytokine profile that is favorable for anti-tumor immunity, without excessive production of myeloid cytokines such as IL6 which are associated with cytokine release syndrome (CRS)
Treatment with AMV564 yields significant expansion of the T cell repertoire including T cell clones not detectable at baseline, and expansion of anti-tumor T cells, in cancer patients
Poster Details:
Session Title: Immunomodulatory Agents and Interventions
Session Start Date/Time: Saturday, April 10, 2021, 8:30 AM – 11:59 PM ET
Title: MDSC suppress the T cell repertoire and contribute to a pathologic cytokine milieu in cancer patients
Authors: Sterling C. Eckard, et al.
Abstract: 528
The abstract is available on the AACR (Free AACR Whitepaper) Annual Meeting website, and in addition, the poster is available on the Presentations & Publications page on the Amphivena website.
About AMV564
AMV564 relieves immune suppression via targeted depletion of MDSC and drives T cell activation and polarization to restore anti-cancer immunity. To date, over 90 patients have received AMV564 across three Phase 1 clinical trials for patients with solid tumors, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS).